EVFM Evofem Biosciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1618835 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.0%
TTM net income YoY-133.9%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR9.3%
Net income 3-yr CAGR—
Margins
Gross margin75.9%
Operating margin-16.8%
Net margin-71.7%
FCF margin—
EBITDA margin-16.7%
Returns
ROE—
ROA-120.6%
ROIC (approx.)—
Asset turnover1.68x
Leverage & solvency
Liabilities / assets1,184.7%
Debt / equity—
Current ratio0.07x
Interest coverage-1.18x
Cash quality & payout
Operating cash flow / net income0.05x
Accruals ratio-115.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $20.18M | $19.36M |
| Cost of revenue | $4.62M | $3.83M |
| Gross profit | $15.57M | $15.53M |
| R&D expense | — | $1.84M |
| SG&A expense | $7.39M | $11.56M |
| Operating income | $3.37M | -$7.68M |
| Interest expense | $2.37M | $2.24M |
| Pretax income | $393,000 | -$8.86M |
| Income tax | $2,000 | — |
| Net income | $391,000 | -$8.86M |
| EBITDA | $3.39M | -$7.65M |
| EPS (basic) | 0.00 | -0.11 |
| EPS (diluted) | 0.00 | -0.11 |
| Weighted avg. shares (diluted) | 6.42B | 80.00M |
| Balance sheet | ||
| Cash & equivalents | $578,000 | $741,000 |
| Receivables | $12.48M | $9.83M |
| Inventory | $1.13M | $1.58M |
| Current assets | $15.28M | $13.61M |
| PP&E, net | $418,000 | $458,000 |
| Intangibles | $4.35M | $9.60M |
| Total assets | $20.27M | $23.79M |
| Current liabilities | $84.82M | $80.45M |
| Short-term debt | $147,000 | $135,000 |
| Total liabilities | $89.71M | $90.26M |
| Shareholders' equity | -$74.34M | -$71.26M |
| Shares outstanding | 126.69M | 113.36M |
| Cash flow statement | ||
| Operating cash flow | -$1.99M | -$3.88M |
| Capital expenditure | $5,000 | $14,000 |
| Free cash flow | -$2.00M | -$3.90M |
| Investing cash flow | -$62,000 | -$569,000 |
| Financing cash flow | $1.89M | $4.62M |
| Depreciation & amortization | $19,000 | $30,000 |
| Stock-based compensation | $166,000 | $847,000 |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.